Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

IMpower133: Gene expression analysis in long-term survivors with ES-SCLC treated with first-line carboplatin and etoposide ± atezolizumab

ESMO-Virtual-Plenary-2021-1000x250-June
Start date
17 Jun 2021
End date
18 Jun 2021

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

Programme

Thursday, 17 June 2021

18:15-19:15 CEST

Welcome and introduction, Scientific background and context

Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, Spain

IMpower133: Gene expression analysis in long-term survivors with ES-SCLC treated with first-line carboplatin and etoposide ± atezolizumab

Stephen Liu, Lombardi Cancer Center, Georgetown University, Washington, DC, USA

Critical analysis and perspectives

Anne-Marie Dingemans, Erasmus MC - University Medical Center, Rotterdam, the Netherlands

Discussion and Q&A (i)

Faculty and online audience

Friday, 18 June 2021

12:00-13:00 CEST (18:00 HKT / 19:00 JST / 20:00 AEST)

Webcast of 17 June presentations, Discussion and Q&A (ii)

Faculty and online audience:

Chair: James CH Yang, National Taiwan University Cancer Center, Taipei, Taiwan

Stephen Liu, Lombardi Cancer Center Georgetown University, Washington, DC, USA

Anne-Marie Dingemans, Erasmus MC - University Medical Center, Rotterdam, the Netherlands

Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Hidehito Horinouchi, National Cancer Center - Tsukiji Campus, Chuo-ku,  Japan

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings